Top in hem/onc: Therapeutic heparin for COVID-19, TV viewing and VTE risk
Click Here to Manage Email Alerts
New research showed that hospitalized patients with COVID-19 who received therapeutic full-dose heparin were less likely to die than those who received prophylactic low-dose heparin. It was the top story in hematology/oncology last week.
Another top story included results from the REGARDS study. Researchers hypothesized that more TV viewing would correlate with a higher risk for venous thromboembolism; however, they found no evidence of an association.
Read these and more top stories in hematology/oncology below:
Benefit of full-dose heparin for patients with COVID-19 warrants ‘new standard of care’
Early administration of full-dose heparin slowed the thrombo-inflammatory process and reduced the risk for severe disease and death among moderately ill hospitalized patients with COVID-19, according to a study published in MedRxiv. Read more.
TV viewing may not be risk factor for venous thromboembolism, study shows
TV or not TV: The relationship between viewing it and venous thromboembolism risk, when accounting for physical activity and other risk factors, is the question. Read more.
Oral paclitaxel plus encequidar shows superior tumor response in metastatic breast cancer
Among patients with metastatic breast cancer, oral paclitaxel and encequidar demonstrated superior tumor response rate compared with IV paclitaxel, according to research presented at ASCO 2021. Read more.
FDA grants fast track status to Cosela for triple-negative breast cancer
The FDA granted fast track designation to trilaciclib for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple-negative breast cancer, according to the agent’s manufacturer. Read more.
Single abelacimab dose reduces VTE after knee replacement surgery
A single IV dose of the factor XI monoclonal antibody abelacimab appeared to be superior to daily enoxaparin for preventing venous thromboembolism after total knee arthroplasty, according to randomized study results. Read more.